6:28 PM
 | 
Oct 18, 2012
 |  BC Extra  |  Company News

FDA approves ThromboGenics' ocriplasmin

FDA approved a BLA from ThromboGenics N.V. (Euronext:THR) for Jetrea ocriplasmin to treat symptomatic vitreomacular adhesion (VMA). The company plans to launch...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >